Opening book details…
About this book
Exploring Non-orthosteric Interactions with a Series of Potent and Selective A3 Antagonists by Darío Miranda-Pastoriza, Rodrigo Bernárdez, Jhonny Azuaje, Rubén Prieto-Díaz, Maria Majellaro, Ashish V. Tamhankar, Lucien Koenekoop, Alejandro González, Claudia Gioé-Gallo, Ana Mallo-Abreu, José Brea, M. Isabel Loza, Aitor García-Rey, Xerardo... is a book available to read on EtoBox.
- Author
- Darío Miranda-Pastoriza, Rodrigo Bernárdez, Jhonny Azuaje, Rubén Prieto-Díaz, Maria Majellaro, Ashish V. Tamhankar, Lucien Koenekoop, Alejandro González, Claudia Gioé-Gallo, Ana Mallo-Abreu, José Brea, M. Isabel Loza, Aitor García-Rey, Xerardo...
- Published
- 2022
- Language
- EN
More by Darío Miranda-Pastoriza, Rodrigo Bernárdez, Jhonny Azuaje, Rubén Prieto-Díaz, Maria Majellaro, Ashish V. Tamhankar, Lucien Koenekoop, Alejandro González, Claudia Gioé-Gallo, Ana Mallo-Abreu, José Brea, M. Isabel Loza, Aitor García-Rey, Xerardo...
Similar books
- Novel Potent Selective Orally Active S1P5 Receptor Antagonists — Bin Ma, Kevin M. Guckian, Xiao-gao Liu, Chunhua Yang, Bing Li, Robert Scannevin, Michaël Mingueneau, Annabelle Drouillard & Thierry Walzer (2021)
- Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2 — Minh H. Nguyen, Onur Atasoylu, Liangxing Wu, Kanishk Kapilashrami, Michelle Pusey, Karen Gallagher, Cheng-Tsung Lai, Peng Zhao, Joseph Barbosa, Kai Liu, Chunhong He, Colin Zhang, Evan D. Styduhar, Michael R. Witten, Yaoyu Chen, Luping Lin, Yan-ou Yang,... (2022)
- Selective A3 Adenosine Receptor Antagonist Radioligand for Human and Rodent Species — R. Rama Suresh, Zhan-Guo Gao, Veronica Salmaso, Eric Chen, Ryan G. Campbell, Russell B. Poe, Theodore E. Liston & Kenneth A. Jacobson (2022)
- Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors — Yan Chen, Rajinder Singh, Nan Lin, Vanessa Taylor, Esteban S. Masuda & Donald G. Payan (2022)
- Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies — Joshua S. Alford, John W. Lampe, Dorothy Brach, Richard Chesworth, Kat Cosmopoulos, Kenneth W. Duncan, Sean T. Eckley, Jeffrey L. Kutok, Alejandra Raimondi, Thomas V. Riera, Brian Shook, Cuyue Tang, Jennifer Totman & Neil A. Farrow (2022)
- Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist — Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Kei Masuda, Norio Ohyabu, Yoshihiro Banno, Norihito Tokunaga, Tetsuji Kawamoto, Yoshihide Tomata, Yasumi Kumagai, Motoo Iida, Yoichi Nagano, Mariko Yoneyama-Hirozane, Yuji... (2022)